In the Phase II TAPUR trial, palbociclib monotherapy demonstrated "modest antitumor activity" in heavily pretreated non-small cell lung cancer patients with CDKN2A alterations.
In a Phase Ia/Ib study, the anti-TIGIT antibody and Tecentriq combination had better anti-tumor activity than tiragolumab alone, particularly in PD-L1 expressing lung cancers.
The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.
Christiana Care researchers have identified a unique protospacer adjacent motif site that allows them to knock out the NRF2 gene in tumor cells while leaving normal cells alone.
The decision is based on pooled single-arm trial data demonstrating the agent's ability to prolong progression-free survival and shrink patients' tumors.
